Rhinoconjunctivitis News and Research

RSS

Stapokibart shows promise in reducing nasal congestion in seasonal allergy patients, study finds

The efficacy and safety of stapokibart as an in patients with seasonal allergic rhinitis (SAR).

9 Feb 2024

Climate change and the future of allergic disease management

As we head into the new year, some issues may be coming into sharper focus for those involved in allergy-immunology issues.

13 Dec 2023

Does maternal peanut consumption protect against infant peanut allergies?

Researched determined whether maternal consumption of peanuts while breastfeeding protects the infant from allergies.

25 Apr 2023

Allergies can have serious, far-reaching consequences on adolescents

Although allergies affect more than 50 million Americans, they are occasionally misunderstood and can be seen as a minor condition. An article published in Annals of Allergy, Asthma and Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology shows allergies can have serious, far-reaching consequences, especially on adolescent sufferers.

24 May 2018

Tackling food allergies: is immunotherapy the answer?

Food allergies affect approximately 8% of school children in the United States and the United Kingdom. The highest prevalence of food allergies is in Australia affecting approximately 10% of young children. It is lower in the developing world.

7 Aug 2017

Tianjiu therapy enhances daily quality of life for allergic rhinitis patients, study finds

The School of Chinese Medicine of Hong Kong Baptist University (HKBU) recently conducted a "Tianjiu therapy for allergic rhinitis: A double-blinded randomised Placebo-controlled clinical trial".

13 Jun 2017

Atopix raises additional development capital to investigate OC459 for treatment of asthma

Atopix Therapeutics Limited, a UK biopharmaceutical company developing a novel class of medicines to treat atopic dermatitis and severe asthma, today announced that it has raised additional development capital to advance its lead product OC459 for the treatment of asthma.

17 Jun 2015

Atopix presents positive results of Phase IIb asthma study at AAAAI meeting

Atopix Therapeutics Ltd ("Atopix"), a biopharmaceutical company developing innovative CRTH2 antagonists for allergic disease, announced the results of a Phase IIb asthma study with their lead compound OC459 at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting , San Diego, California, USA on March 1st.

3 Mar 2014

Atopix awarded grant to pursue development of OC459 for atopic dermatitis

Atopix Therapeutics Ltd, a biopharmaceutical company developing a novel class of anti-allergic medicines, has been awarded a £1.7 million grant from the UK Biomedical Catalyst fund to pursue development of OC459 in the treatment of moderate-to-severe atopic dermatitis (a form of eczema).

29 May 2013

Review article shows sublingual immunotherapy may be useful for allergic rhinitis, asthma

In an examination of a type of treatment for allergic rhinitis and asthma that is used in Europe but not approved by the U.S. Food and Drug Administration, researchers found moderate strength in the evidence from previous studies to support the use of sublingual immunotherapy for the treatment of these conditions, according to an article in the March 27 issue of JAMA.

27 Mar 2013

Oral drops are good for treating symptoms of allergies, allergic asthma in some people: Review

A scientific review of 63 published studies affirms that putting small amounts of purified grasses, ragweed, dust mites, pollen and mold, in liquid drops under the tongue is a safe and effective alternative to weekly injections of those allergens or the use of other medications, in treating symptoms of allergies and allergic asthma in some people.

27 Mar 2013

Researchers to present new results for Merck's allergy immunotherapy tablets at AAAAI meeting

Merck, known as MSD outside the United States and Canada, today announced that researchers will present new data analyses of the safety and efficacy of the company's investigational allergy immunotherapy tablets (AITs) for ragweed pollen (Ambrosia artemisiifolia) and grass pollen (Phleum pratense) at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.

25 Feb 2013

Circassia announces results from ToleroMune cat allergy phase II clinical study

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical study showing that a short course of just four doses of its ToleroMune cat allergy therapy maintained improvements in patients' symptoms two years after the start of treatment.

25 Feb 2013

Diet plays key role in severe childhood allergic disorders

Study findings suggest that children and adolescents who eat fast food three times a week or more have a greater risk for severe asthma, rhinoconjunctivitis, and eczema than those who do not.

25 Jan 2013

HAL Allergy completes enrollment in SUBLIVAC FIX Phleum pratense Phase II trial

HAL Allergy B.V. today announced that it has successfully completed patient enrollment in its Phase II trial with SUBLIVAC FIX Phleum pratense.

19 Dec 2012

Circassia commences ToleroMune phase 3 trial in cat allergen-induced rhinoconjunctivitis

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the start of a pivotal phase 3 trial of its investigational ToleroMune cat allergy treatment for cat allergen-induced rhinoconjunctivitis.

4 Oct 2012

Promising results with SLIT for childhood grass pollen allergy

High-dose sublingual immunotherapy effectively reduces allergic symptoms and medication use in children with grass pollen–allergic rhinoconjunctivitis, show study results.

31 Aug 2012

Common ragweed may induce airways irritation through terpenoids

Allergy to pollen of common ragweed is increasingly affecting patients and is second only to grass pollen in terms of incidence in the general population of many European countries.

6 Aug 2012

Allergy and asthma linked to the air pupils breathe

Poor air quality inside classrooms could play a role in the development of asthma and allergies in children, the results of a French study show.

31 Jul 2012

Sunovion launches ZETONNA Nasal Aerosol for allergic rhinitis

Sunovion Pharmaceuticals Inc. today announced the nationwide availability of ZETONNA (ciclesonide) Nasal Aerosol, 74 mcg once-daily, for the treatment of allergic rhinitis (AR), also known as hay fever or nasal allergies. ZETONNA is a corticosteroid indicated for the treatment of symptoms associated with seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and adolescents 12 years of age and older.

30 Jul 2012